Cargando…

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China

BACKGROUND: The cost-effectiveness of human papillomavirus (HPV) vaccination in women pre-sexual debut has been demonstrated in many countries. This study aimed to estimate the cost-effectiveness of a 3-dose bivalent HPV vaccination at ages 12 to 55 year in both rural and urban settings in China. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi-Jun, Zhang, Qian, Hu, Shang-Ying, Zhao, Fang-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768405/ https://www.ncbi.nlm.nih.gov/pubmed/26919850 http://dx.doi.org/10.1186/s12885-016-2207-3

Ejemplares similares

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China
por: Zhang, Qian, et al.
Publicado: (2016)

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan
por: Liu, Pang-Hsiang, et al.
Publicado: (2010)

Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China
por: Zou, Maosheng, et al.
Publicado: (2023)

Cost-effectiveness of human papillomavirus vaccination in Germany
por: Damm, Oliver, et al.
Publicado: (2017)

Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer
por: Cid-Arregui, Angel
Publicado: (2009)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward
por: Zhao, Xue-Lian, et al.
Publicado: (2023)

Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China
por: Mo, Xiuting, et al.
Publicado: (2017)

Cost-effectiveness of Human Papillomavirus Vaccination in the United States
por: Chesson, Harrell W., et al.
Publicado: (2008)

Cost Effectiveness of a Potential Vaccine for Human papillomavirus
por: Sanders, Gillian D., et al.
Publicado: (2003)

Cost-effectiveness of different human papillomavirus vaccines in Singapore
por: Lee, Vernon J, et al.
Publicado: (2011)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China
por: Ye, Ze-Hao, et al.
Publicado: (2021)

Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
por: Shi, Wenchuan, et al.
Publicado: (2021)

Variation in Human Papillomavirus Vaccination Effectiveness in the US by Age at Vaccination
por: Egemen, Didem, et al.
Publicado: (2022)

Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study
por: Van Minh, Hoang, et al.
Publicado: (2017)

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
por: Jiang, Y, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2019)

Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine
por: Nicoli, Francesco, et al.
Publicado: (2022)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers
por: Nayereh, Khadem Ghaebi, et al.
Publicado: (2012)

Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer
por: Kamolratanakul, Supitcha, et al.
Publicado: (2021)

Prevalence of High-Risk Human Papillomavirus in Cervical Intraepithelial Neoplasia in the Pre-Vaccine Era — China, 2017–2018
por: Bao, Heling, et al.
Publicado: (2022)

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
por: Westra, Tjalke A, et al.
Publicado: (2013)

Cost-effectiveness analysis of vaccination against COVID-19 in China
por: Zhou, Huixuan, et al.
Publicado: (2023)

Acceptability of deferring the start of cervical cancer screening to age 30 for women vaccinated against human papillomavirus
por: Martello, Gessica, et al.
Publicado: (2023)

Vaccination against human papillomavirus
por: Mello, Claudia Figueiredo
Publicado: (2013)

Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity
por: Kudo, Risa, et al.
Publicado: (2022)

A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines
por: Guerrero, Anna Melissa, et al.
Publicado: (2015)

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
por: Mahumud, Rashidul Alam, et al.
Publicado: (2019)

Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women
por: Onuki, Mamiko, et al.
Publicado: (2022)

Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal()
por: Brennan, Timothy, et al.
Publicado: (2022)

Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine
por: Turner, Hugo C., et al.
Publicado: (2013)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness
por: Jit, Mark, et al.
Publicado: (2021)

Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys
por: Sayinzoga, Felix, et al.
Publicado: (2023)

Costs of delivering human papillomavirus vaccination in Tanzania
por: Struckmann, V, et al.
Publicado: (2022)

Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model
por: Zhou, Liangru, et al.
Publicado: (2022)

Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study
por: Li, Yuwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8t2vlls78ou4vlbavq7f5b84el